利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.02 秒)

    SULFONYLAMINO-CARBONSÄURE-N-ARYLAMIDE ALS GUANYLATCYCLASE-AKTIVATOREN
    3.
    发明授权
    SULFONYLAMINO-CARBONSÄURE-N-ARYLAMIDE ALS GUANYLATCYCLASE-AKTIVATOREN 有权
    磺酰胺亚胺基亚胺酰胺ALS GUANYLATCYCLASE-AKTIVATOREN

    公开(公告)号：EP1095015B1

    公开(公告)日：2005-06-01

    申请号：EP99936460.7

    申请日：1999-06-25

    申请人： Aventis Pharma Deutschland GmbH

    发明人： SCHINDLER, Ursula ,  SCHÖNAFINGER, Karl ,  STROBEL, Hartmut

    IPC分类号： C07C311/21

    CPC分类号： C07F9/4056 ,  C07C311/21 ,  C07D207/27 ,  C07D207/325 ,  C07D207/404 ,  C07D209/08 ,  C07D209/48 ,  C07D215/48 ,  C07D217/02 ,  C07D217/24 ,  C07D231/56 ,  C07D235/18 ,  C07D241/20 ,  C07D249/18 ,  C07D295/135 ,  C07D295/192 ,  C07D307/91 ,  C07D311/16 ,  C07D317/60 ,  C07D409/04 ,  C07F9/3882

    摘要： The invention relates to compounds of formula (I), wherein A?1, A2, R2 and R3¿ have the meanings cited in the claims. Said compounds are valuable pharmaceutical active substances for the treatment and prophylaxis of diseases, e.g. cardiovascular diseases such a hypertension, angina pectoris, heart failures, thrombosis or atherosclerosis. The compounds of formula (I) have the ability of modulating endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for treatment and prophylaxis of pathological states associated with cGMP metabolic disorders. The invention also relates to the use of compounds of formula (I) for treatment and prophylaxis of the above-mentioned pathological states and for producing corresponding medicaments, to pharmaceutical preparations containing said compounds and to a method of production.

    摘要翻译： 本发明涉及式Ⅰ化合物，其中A 1，A 2，R 2和R 3具有权利要求中所示的含义，它们是用于治疗和预防的有价值的药物活性化合物 的疾病，例如心血管疾病如高血压，心绞痛，心功能不全，血栓形成或动脉粥样硬化。 式I的化合物具有调节环鸟苷酸（cGMP）的内源性产生的能力，并且通常适用于治疗和预防与扰动的cGMP平衡相关的疾病状态。 本发明涉及式I化合物用于治疗和预防指定疾病状态及其制备药物的用途，式I化合物，包含它们的药物制剂及其制备方法。

    ACYLATED ARYLCYCLOALKYLAMINES AND THEIR USE AS PHARMACEUTICALS
    4.
    发明公开
    ACYLATED ARYLCYCLOALKYLAMINES AND THEIR USE AS PHARMACEUTICALS 审中-公开
    ACYLIERTE ARYLCYCLOALKYLAMINE UND IHRE ANWENDUNG ALS ARZNEIMITTELWIRKSTOFF

    公开(公告)号：EP1529031A1

    公开(公告)日：2005-05-11

    申请号：EP03784056.8

    申请日：2003-07-24

    申请人： Aventis Pharma Deutschland GmbH

    发明人： STROBEL, Hartmut ,  WOHLFART, Paulus ,  BELOW, Peter

    IPC分类号： C07C233/58 ,  A61K31/166 ,  A61P9/00 ,  C07D263/34 ,  C07D213/82 ,  C07C237/38 ,  C07D295/14

    CPC分类号： C07D213/82 ,  C07C233/65 ,  C07C237/38 ,  C07C311/21 ,  C07C2601/02 ,  C07D209/08 ,  C07D215/54 ,  C07D231/14 ,  C07D235/08 ,  C07D241/24 ,  C07D263/34 ,  C07D277/56 ,  C07D295/155 ,  C07D333/38 ,  C07D401/04 ,  C07D409/04

    摘要： The present invention relates to acylated arylcycloalkylamines of the formula I, in which R1, R2 and n have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds which are useful in the treatment of various disease states including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency. They upregulate the expression of the enzyme endothelial nitric oxide (NO) synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

    摘要翻译： 本发明涉及式I的酰化芳基环烷基胺，其中R 1，R 2和n具有权利要求中所示的含义。 式I化合物是有用的药理学活性化合物，其可用于治疗包括心血管疾病如动脉粥样硬化，血栓形成，冠状动脉疾病，高血压和心脏功能不全等各种疾病状态。 它们上调酶内皮一氧化氮（NO）合酶的表达，并且可以用于需要所述酶的表达增加或NO水平升高或NO水平降低的标准化的条件下。 本发明还涉及式I化合物的制备方法，其用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。

    SUBSTITUIERTE 4-AMINO-2-ARYL-CYCLOPENTA D]PYRIMIDINE, IHRE HERSTELLUNG, IHRE VERWENDUNG UND SIE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE
    5.
    发明公开
    SUBSTITUIERTE 4-AMINO-2-ARYL-CYCLOPENTA D]PYRIMIDINE, IHRE HERSTELLUNG, IHRE VERWENDUNG UND SIE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE 有权
    取代的4-氨基-2-芳基 - 环戊并[d]嘧啶类，生产，使用和药物制剂含有它们

    公开(公告)号：EP1131302A1

    公开(公告)日：2001-09-12

    申请号：EP99972626.8

    申请日：1999-11-03

    申请人： Aventis Pharma Deutschland GmbH

    发明人： SCHINDLER, Ursula ,  SCHÖNAFINGER, Karl ,  STROBEL, Hartmut

    IPC分类号： C07D239/70 ,  C07D401/12 ,  A61K31/517

    CPC分类号： C07D401/12 ,  C07D239/70

    摘要： The present invention relates to compounds of formula (I) wherein R?1, R2 and R3¿ have the meanings given in the claims. Said compounds are valuable active agents in medicaments for the treatment and prophylaxis of diseases, for example cardiovascular diseases such as hypertension, angina pectoris, heart failure, thrombosis and atherosclerosis. The compounds of formula (I) are able to modulate the body's own production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the treatment and prophylaxis ofisorders associated with an impaired cGMP balance. The invention also relates to methods for producing compounds of formula (I), to their use in the treatment and prophylaxis of the above diseases and in the preparation of medicaments for such diseases, and to pharmaceutical preparations containing the compounds of formula (I).

    SUBSTITUIERTE ISOINDOLONE UND IHRE VERWENDUNG ALS CYCLISCHE GMP MODULATOREN IN ARZNEIMITTELN
    7.
    发明授权
    SUBSTITUIERTE ISOINDOLONE UND IHRE VERWENDUNG ALS CYCLISCHE GMP MODULATOREN IN ARZNEIMITTELN 有权
    取代的异吲哚酮及其作为cGMP的调节剂药品

    公开(公告)号：EP1064262B1

    公开(公告)日：2003-02-12

    申请号：EP99907548.4

    申请日：1999-02-12

    申请人： Aventis Pharma Deutschland GmbH

    发明人： SCHINDLER, Ursula ,  SCHÖNAFINGER, Karl ,  STROBEL, Hartmut ,  GROEHN, Viola

    IPC分类号： C07D209/48 ,  A61K31/40 ,  C07D401/04 ,  C07D409/04

    CPC分类号： C07D209/48 ,  C07D401/04 ,  C07D409/04

    摘要： The invention relates to substituted isoindolon derivatives of formula (I), wherein R?1, R2, R3, R4, R5, R6 and R7¿ have the meanings cited in the description. Said derivatives represent valuable active substances in medicaments for the therapy and prophylaxis of diseases, e.g. cardiovascular diseases such a hypertension, angina pectoris, heart failures, thrombosis or atherosclerosis. The compounds of formula (I) are capable of modulating endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of pathological states associated with disorders of the cGMP metabolism. The invention also relates to a method for the production of compounds of formula (I), their use in the therapy and prophylaxis of the above-mentioned pathological states and in the production of medicaments for such states. The invention further relates to pharmaceutical preparations containing the compounds of formula (I).